{"id":295328,"date":"2022-11-03T00:00:00","date_gmt":"2022-11-03T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrop0006-2022-biopharma-glaucoma-current-treatment-current-treatment-physician-insights-glaucoma\/"},"modified":"2026-04-14T10:20:37","modified_gmt":"2026-04-14T10:20:37","slug":"cutrop0006-2022-biopharma-glaucoma-current-treatment-current-treatment-physician-insights-glaucoma-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrop0006-2022-biopharma-glaucoma-current-treatment-current-treatment-physician-insights-glaucoma-us\/","title":{"rendered":"Glaucoma &#8211; Current Treatment &#8211; Current Treatment: Physician Insights &#8211; Glaucoma (US)"},"content":{"rendered":"<p>Glaucoma is a progressive disease of the optic nerve, caused by high intraocular pressure (<abbr title=\"intraocular pressure\">IOP<\/abbr>); it is one of the leading causes of vision loss in the United States. Glaucoma treatment aims to lower and stabilize <abbr title=\"intraocular pressure\">IOP<\/abbr>. Pharmacotherapy is widely used, and nonpharmacological interventions continue to gain traction in the treatment of the major subtype of the disease, primary open-angle glaucoma (<abbr title=\"open-angle glaucoma\">OAG<\/abbr>). Although the U.S. glaucoma therapy market is crowded and highly genericized, branded therapies play an important role, particularly in later lines of therapy. Recent-to-market therapies\u2014Alcon\u2019s Rocklatan and AbbVie\u2019s Durysta\u2014have expanded the treatment armamentarium for <abbr title=\"open-angle glaucoma\">OAG<\/abbr>. Among nonpharmacological approaches, incisional glaucoma surgery, laser trabeculoplasty, and developments in devices for micro \/ minimally invasive glaucoma surgery (<abbr title=\"micro \/ minimally invasive glaucoma surgery\">MIGS<\/abbr>) offer additional advances to manage <abbr title=\"open-angle glaucoma\">OAG<\/abbr> patients.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What key differences exist in primary <abbr title=\"open-angle glaucoma\">OAG<\/abbr> treatment between ophthalmologists and optometrists in the United States?<\/li>\n<li>How are more recently launched therapies such as AbbVie\u2019s Durysta and Bausch + Lomb\u2019s Vyzulta faring in later lines of therapies?<\/li>\n<li>How successful is Alcon\u2019s newer once-daily fixed-dose combination (<abbr title=\"fixed-dose combination\">FDC<\/abbr>), Rocklatan, compared with other <abbr title=\"fixed-dose combination\">FDC<\/abbr>s such as twice-daily AbbVie\u2019s Combigan, Thea\u2019s Cosopt, or Alcon\u2019s thrice-daily Simbrinza?<\/li>\n<li>How compelling has Sun Ophthalmics\u2019s Xelpros, a <abbr title=\"benzalkonium chloride\">BAK<\/abbr>-free formulation of latanoprost, proven compared with Pfizer\u2019s Xalatan or generic versions of latanoprost?<\/li>\n<li>Which <abbr title=\"micro \/ minimally invasive glaucoma surgery\">MIGS<\/abbr> devices garner the greatest share among primary <abbr title=\"open-angle glaucoma\">OAG<\/abbr> patients, and does device preference vary between ophthalmologists and optometrists?<\/li>\n<li>Have data from the <abbr title=\"Laser in Glaucoma and Ocular Hypertension\">LiGHT<\/abbr> trial on the use of selective laser trabeculoplasty in early lines of therapy influenced physicians\u2019 use of this approach?<\/li>\n<li>How do ophthalmologists and optometrists envision their treatment of primary <abbr title=\"open-angle glaucoma\">OAG<\/abbr> to evolve over the next three years?<\/li>\n<\/ul>\n<p><b>Product description<\/b><\/p>\n<p><em>Current Treatment: Physician Insights <\/em>provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.<\/p>\n<p><strong>Markets Covered:<\/strong><strong> <\/strong> <strong> <\/strong>United States.<\/p>\n<p><strong>Primary research:<\/strong><strong> <\/strong> Survey of 85 U.S. ophthalmologists and 20 optometrists.<\/p>\n<p><strong>Key drugs covered: <\/strong><!--{C}%3C!%2D%2DStartFragment%20%2D%2D%3E-->Durysta, Vyzulta, Xelpros, Rhopressa, Rocklatan, Combigan, and Simbrinza.<!--{C}%3C!%2D%2DEndFragment%20%2D%2D%3E--><\/p>\n<p><strong>Key companies: <\/strong>Alcon, AbbVie, Sun Ophthalmics, and Bausch + Lomb<\/p>\n<p><strong>Key insights provided<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Factors influencing disease management and treatment decisions.<\/li>\n<li>Drivers and constraints of treatment selection.<\/li>\n<li>Physician-reported treatment practices and brand-level patient shares.<\/li>\n<li>Rationale for changes in treatment approach.<\/li>\n<li>Physician insight on persistency and compliance.<\/li>\n<li>Physician-reported recent \/ anticipated changes in brand usage over the next three years.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-295328","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-glaucoma","biopharma-therapy-areas-ophthalmology","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295328","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295328\/revisions"}],"predecessor-version":[{"id":295479,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295328\/revisions\/295479"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=295328"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}